Literature DB >> 24089561

Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.

Tatiana Chirkova1, Seyhan Boyoglu-Barnum, Kelsey A Gaston, Fahad M Malik, Steven P Trau, Antonius G P Oomens, Larry J Anderson.   

Abstract

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children and causes disease in the elderly and persons with compromised cardiac, pulmonary, or immune systems. Despite the high morbidity rates of RSV infection, no highly effective treatment or vaccine is yet available. The RSV G protein is an important contributor to the disease process. A conserved CX3C chemokine-like motif in G likely contributes to the pathogenesis of disease. Through this motif, G protein binds to CX3CR1 present on various immune cells and affects immune responses to RSV, as has been shown in the mouse model of RSV infection. However, very little is known of the role of RSV CX3C-CX3CR1 interactions in human disease. In this study, we use an in vitro model of human RSV infection comprised of human peripheral blood mononuclear cells (PBMCs) separated by a permeable membrane from human airway epithelial cells (A549) infected with RSV with either an intact CX3C motif (CX3C) or a mutated motif (CX4C). We show that the CX4C virus induces higher levels of type I/III interferon (IFN) in A549 cells, increased IFN-α and tumor necrosis factor alpha (TNF-α) production by human plasmacytoid dendritic cells (pDCs) and monocytes, and increased IFN-γ production in effector/memory T cell subpopulations. Treatment of CX3C virus-infected cells with the F(ab')2 form of an anti-G monoclonal antibody (MAb) that blocks binding to CX3CR1 gave results similar to those with the CX4C virus. Our data suggest that the RSV G protein CX3C motif impairs innate and adaptive human immune responses and may be important to vaccine and antiviral drug development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089561      PMCID: PMC3838285          DOI: 10.1128/JVI.01741-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 3.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

4.  CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells.

Authors:  Liat Bar-On; Tal Birnberg; Kanako L Lewis; Brian T Edelson; Dunja Bruder; Kai Hildner; Jan Buer; Kenneth M Murphy; Boris Reizis; Steffen Jung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

5.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

6.  The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.

Authors:  Fernando P Polack; Pablo M Irusta; Scott J Hoffman; M Paula Schiatti; Guillermina A Melendi; M Florencia Delgado; Federico R Laham; Bhagvanji Thumar; R Michael Hendry; Jose A Melero; Ruth A Karron; Peter L Collins; Steven R Kleeberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

7.  Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.

Authors:  Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

8.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

9.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

10.  Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway.

Authors:  Christine M Oshansky; Thomas M Krunkosky; Jamie Barber; Les P Jones; Ralph A Tripp
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

View more
  49 in total

Review 1.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

Review 2.  Viral manipulation of the host immune response.

Authors:  Allison Christiaansen; Steven M Varga; Juliet V Spencer
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

3.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

4.  Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Authors:  S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Authors:  Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

6.  Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.

Authors:  Hayat Caidi; Congrong Miao; Natalie J Thornburg; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  Antiviral Res       Date:  2018-04-17       Impact factor: 5.970

Review 7.  Recent advances on viral manipulation of NF-κB signaling pathway.

Authors:  Jun Zhao; Shanping He; Arlet Minassian; Junhua Li; Pinghui Feng
Journal:  Curr Opin Virol       Date:  2015-09-15       Impact factor: 7.090

Review 8.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

9.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

10.  Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.

Authors:  Eun-Ju Ko; Young-Man Kwon; Jong Seok Lee; Hye Suk Hwang; Si-Eun Yoo; Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Min Kyoung Cho; You Ri Lee; Fu-Shi Quan; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Nanomedicine       Date:  2014-08-08       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.